5 HT 2 A and 5 HT 2 B receptors contribute to serotonin-induced vascular dysfunction in diabetes

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Nelson, Peter M ^a   Harrod, Jeremy S ^a   Lamping, Kathryn G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; BRL 54443; GLEMANSERIN; LY 272015; NORFENFLURAMINE; RHO KINASE; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; SEROTONIN; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; VASCULAR DISEASE; ANIMAL; C57BL MOUSE; DIABETIC ANGIOPATHY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

ANIMALS; AORTA; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN KINASE INHIBITORS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RHO-ASSOCIATED KINASES; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

MLCS; MLOWN;

EID: 84872789899     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/398406     Document Type: Article

References (50)

1. 2 receptors mediating contraction in vascular smooth muscle. Journal of Pharmacology and Experimental Therapeutics 1981 218 2 421 425 2-s2.0-0019395677 (Pubitemid 11044118)
2. Lamping K. G., Faraci F. M., Role of sex differences and effects of endothelial NO synthase deficiency in responses of carotid arteries to serotonin. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 4 523 528 2-s2.0-0035048427 (Pubitemid 32323383)
3. Lamping K. G., Kanatsuka H., Eastham C. L., Chilian W. M., Marcus M. L., Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circulation Research 1989 65 2 343 351 2-s2.0-0024327079 (Pubitemid 19194620)
4. McKune C. M., Watts S. W., Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. Journal of Pharmacology and Experimental Therapeutics 2001 297 1 88 95 2-s2.0-0035083969 (Pubitemid 32242566)
5. Nuno D. W., Korovkina V. P., England S. K., Lamping K. G., RhoA activation contributes to sex differences in vascular contractions. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 9 1934 1940 2-s2.0-34548182092 10.1161/ATVBAHA.107.144675 (Pubitemid 47312301)
6. Dreja K., Voldstedlund M., Vinten J., Tranum-Jensen J., Hellstrand P., Swärd K., Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 8 1267 1272 2-s2.0-0036344517 10.1161/01.ATV. 0000023438.32585.A1 (Pubitemid 34875735)
7. Banes A. K. L., Watts S. W., Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension 2002 39 2, part 2 394 398 2-s2.0-0036179084 10.1161/hy02t2.102793 (Pubitemid 34165155)
8. Banes A. K. L., Watts S. W., Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacology 2003 3 12 2-s2.0-2342481856 10.1186/1471-2210-3-12 (Pubitemid 38729266)
9. Banes A. K. L., Watts S. W., Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1B) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat. Hypertension 2001 38 4 891 895 2-s2.0-0035725939 (Pubitemid 34258688)
10. Ishida T., Kawashima S., Hirata K. I., Sakoda T., Shimokawa Y., Miwa Y., Inoue N., Ueyama T., Shiomi M., Akita H., Yokoyama M., Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 2001 103 9 1289 1295 2-s2.0-0035814953 (Pubitemid 32221354)
11. Watts S. W., Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. Hypertension 2002 39 3 825 829 2-s2.0-0036199926 10.1161/hy0302.104668 (Pubitemid 34252884)
12. Russell A., Banes A., Berlin H., Fink G. D., Watts S. W., 5-Hydroxytryptamine(2B) receptor function is enhanced in the N ω -nitro-L-arginine hypertensive rat. Journal of Pharmacology and Experimental Therapeutics 2002 303 1 179 187 2-s2.0-0036786399 10.1124/jpet.102.037390
13. Ansar S., Vikman P., Nielsen M., Edvinsson L., Cerebrovascular ETB, 5-HT1B, and AT1 receptor upregulation correlates with reduction in regional CBF after subarachnoid hemorrhage. American Journal of Physiology-Heart and Circulatory Physiology 2007 293 6 H3750 H3758 2-s2.0-36849086026 10.1152/ajpheart.00857.2007 (Pubitemid 350230923)
14. Mayhan W. G., Effect of diabetes mellitus on responses of the basilar artery in rats to products released by platelets. Stroke 1992 23 10 1499 1503 2-s2.0-0026697501
15. Mayhan W. G., Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. American Journal of Physiology-Heart and Circulatory Physiology 1989 256 3, part 2 H621 H625 2-s2.0-0024596673
16. Nuno D. W., Lamping K. G., The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes. Experimental Diabetes Research 2010 2010 11 176361 2-s2.0-77953925092
17. Nuno D. W., Harrod J. S., Lamping K. G., Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice. American Journal of Physiology-Heart and Circulatory Physiology 2009 297 4 H1469 H1477 2-s2.0-70349616568 10.1152/ajpheart.00407.2009
18. Lamping K. G., Enhanced contractile mechanisms in vasospasm: is endothelial dysfunction the whole story? Circulation 2002 105 13 1520 1522 2-s2.0-0037007047 10.1161/01.CIR.0000014120.90086.51 (Pubitemid 34297621)
19. + channels in mesenteric arterial smooth muscle cells of OLETF rats. Progress in Biophysics and Molecular Biology 2010 103 1 88 94 10.1016/j.pbiomolbio.2010.02.003
20. Cushing D. J., Cohen M. L., Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2- receptor heterogeneity. Journal of Pharmacology and Experimental Therapeutics 1993 264 1 193 200 2-s2.0-0027486492 (Pubitemid 23309201)
21. Breitenlechner C., Gaßel M., Hidaka H., Kinzel V., Huber R., Engh R. A., Bossemeyer D., Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 2003 11 12 1595 1607 2-s2.0-0344234281 10.1016/j.str.2003.11.002 (Pubitemid 37510358)
22. Ikenoya M., Hidaka H., Hosoya T., Suzuki M., Yamamoto N., Sasaki Y., Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. Journal of Neurochemistry 2002 81 1 9 16 2-s2.0-0036077667 10.1046/j.1471-4159.2002.00801.x (Pubitemid 34808850)
23. Ketsawatsomkron P., Stepp D. W., Fulton D. J., Marrero M. B., Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of Protein Tyrosine Phosphatase-1B. Vascular Pharmacology 2010 53 3-4 160 168 2-s2.0-77956186614 10.1016/j.vph.2010.06.001
24. Mayhan W. G., Faraci F. M., Heistad D. D., Responses of cerebral arterioles to adenosine 5 ′ -diphosphate, serotonin, and the thromboxane analogue U-46619 during chronic hypertension. Hypertension 1988 12 6 556 561 2-s2.0-0024242895 (Pubitemid 19030500)
25. Sakurada S., Takuwa N., Sugimoto N., Wang Y., Seto M., Sasaki Y., Takuwa Y., Ca2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circulation Research 2003 93 6 548 556 2-s2.0-0141794500 10.1161/01.RES.0000090998.08629.60 (Pubitemid 37163235)
26. Porter R. H. P., Benwell K. R., Lamb H., Malcolm C. S., Allen N. H., Revell D. F., Adams D. R., Sheardown M. J., Functional characterization of agonists at recombinant human 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in CHO-K1 cells. British Journal of Pharmacology 1999 128 1 13 20 2-s2.0-0032858740 10.1038/sj.bjp.0702751 (Pubitemid 29425262)
27. Zgombick J. M., Schechter L. E., Macchi M., Hartig P. R., Branchek T. A., Weinshank R. L., Human gene S31 encodes the pharmacologically defined serotonin 5- hydroxytryptamine(1E) receptor. Molecular Pharmacology 1992 42 2 180 185 2-s2.0-0027080085 (Pubitemid 23026146)
28. McLean S. L., Woolley M. L., Thomas D., Neill J. C., Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology 2009 206 3 403 414 2-s2.0-70349575345 10.1007/s00213-009-1618-0
29. Cussac D., Newman-Tancredi A., Quentric Y., Carpentier N., Poissonnet G., Parmentier J. G., Goldstein S., Millan M. J., Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn-Schmiedeberg's Archives of Pharmacology 2002 365 3 242 252 2-s2.0-0036193721 10.1007/s00210-001-0505-y (Pubitemid 34212235)
30. Knight A. R., Misra A., Quirk K., Benwell K., Revell D., Kennett G., Bickerdike M., Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 2004 370 2 114 123 2-s2.0-4544261771 10.1007/s00210-004-0951-4 (Pubitemid 39222863)
31. Ni W., Wilhelm C. S., Bader M., Murphy D. L., Lookingland K., Watts S. W., (+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-hydroxytryptamine or 5-hydroxytryptamine transporter. Journal of Pharmacology and Experimental Therapeutics 2005 314 3 953 960 2-s2.0-23944495391 10.1124/jpet.105.087080 (Pubitemid 41205957)
32. Tanaka N., Nakamura E., Ohkura M., Kuwabara M., Yamashita A., Onitsuka T., Asada Y., Hisa H., Yamamoto R., Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery. Clinical and Experimental Pharmacology and Physiology 2008 35 7 836 840 2-s2.0-44249097091 10.1111/j.1440-1681.2008.04933.x (Pubitemid 351725242)
33. Galzin A. M., Delahaye M., Hoornaert C., McCort G., O'Connor S. E., Effects of SL 65.0472, a novel 5-HT receptor antagonist, on 5-HT receptor mediated vascular contraction. European Journal of Pharmacology 2000 404 3 361 368 2-s2.0-0034703568 10.1016/S0014-2999(00)00630-0
34. Verheggen R., Werner I., Lücker A., Brüss M., Göthert M., Kaumann A. J., 5-Hydroxytryptamine-induced contraction of human temporal arteries coexpressing 5-HT2A receptors and wild-type or variant (Phe124Cys) 5-HT1B receptors: increased contribution of 5-HT1B receptors to the total contractile amplitude in arteries from Phe124Cys heterozygous individuals. Pharmacogenetics and Genomics 2006 16 8 601 607 2-s2.0-33746255668 10.1097/01.fpc.0000220564.52348.63 (Pubitemid 44100204)
35. Faraci F. M., Sigmund C. D., Vascular biology in genetically altered mice: smaller vessels, bigger insight. Circulation Research 1999 85 12 1214 1225 2-s2.0-0033533988 (Pubitemid 30430628)
36. Ryan M. J., Didion S. P., Davis D. R., Faraci F. M., Sigmund C. D., Endothelial dysfunction and blood pressure variability in selected inbred mouse strains. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 1 42 48 2-s2.0-0036144727 10.1161/hq0102.101098 (Pubitemid 34076230)
37. Didion S. P., Lynch C. M., Faraci F. M., Cerebral vascular dysfunction in TallyHo mice: a new model of Type II diabetes. American Journal of Physiology-Heart and Circulatory Physiology 2007 292 3 H1579 H1583 2-s2.0-33847763658 10.1152/ajpheart.00939.2006 (Pubitemid 46380246)
38. Bodary P. F., Shen Y., Öhman M., Bahrou K. L., Vargas F. B., Cudney S. S., Wickenheiser K. J., Myers M. G., Eitzman D. T., Leptin regulates neointima formation after arterial injury through mechanisms independent of blood pressure and the leptin receptor/STAT3 signaling pathways involved in energy balance. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 70 76 2-s2.0-33847625379 10.1161/01.ATV.0000252068.89775.ee (Pubitemid 46360382)
39. Senador D., Kanakamedala K., Irigoyen M. C., Morris M., Elased K. M., Cardiovascular and autonomic phenotype of db/db diabetic mice. Experimental Physiology 2009 94 6 648 658 2-s2.0-65649109348 10.1113/expphysiol.2008.046474
40. Souza-Smith F. M., Katz P. S., Trask A. J., Stewart J. A., Lord K. C., Varner K. J., Vassallo D. V., Lucchesi P. A., Mesenteric resistance arteries in type 2 diabetic db/db mice undergo outward remodeling. PLoS ONE 2011 6 8, article e23337 2-s2.0-79961150432 10.1371/journal.pone.0023337
41. Bagi Z., Erdei N., Toth A., Li W., Hintze T. H., Koller A., Kaley G., Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 8 1610 1616 2-s2.0-23244461051 10.1161/01.ATV.0000172688.26838.9f (Pubitemid 41098929)
42. Su W., Guo Z., Randall D. C., Cassis L., Brown D. R., Gong M. C., Hypertension and disrupted blood pressure circadian rhythm in Type 2 diabetic db/db mice. American Journal of Physiology-Heart and Circulatory Physiology 2008 295 4 H1634 H1641 2-s2.0-57049155556 10.1152/ajpheart.00257.2008
43. Goncalves A. C., Tank J., Diedrich A., Hilzendeger A., Plehm R., Bader M., Luft F. C., Jordan J., Gross V., Diabetic hypertensive leptin receptor-deficient db/db mice develop cardioregulatory autonomic dysfunction. Hypertension 2009 53 2 387 392 2-s2.0-59849125655 10.1161/HYPERTENSIONAHA.108. 124776
44. Kanai T., Kuwabara M., Tanaka-Totoribe N., Nakamura E., Matsuo Y., Gamoh S., Suzuki A., Asada Y., Hisa H., Yamamoto R., Insulin induces internalization of the plasma membrane 5-hydroxytryptamine2A (5-HT2A) receptor in the isolated human endothelium-denuded saphenous vein via the phosphatidylinositol 3-kinase pathway. Journal of Pharmacological Sciences 2012 118 2 178 185 10.1254/jphs.11172FP
45. Coleman D. L., Hummel K. P., Studies with the mutation, diabetes, in the mouse. Diabetologia 1967 3 2 238 248 2-s2.0-0014076277 10.1007/BF01222201
46. Coleman D. L., Hummel K. P., Hyperinsulinemia in pre weaning diabetes (db) mice. Diabetologia 1974 10 5 607 610 2-s2.0-0016289615
47. Tuman R. W., Doisy R. J., The influence of age on the development of hypertriglyceridaemia and hypercholesterolaemia in genetically diabetic mice. Diabetologia 1977 13 1 7 11 2-s2.0-0017340793 (Pubitemid 8032031)
48. Hara K., Hirowatari Y., Shimura Y., Takahashi H., Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease. Diabetes Research and Clinical Practice 2011 94 2 167 171 10.1016/j.diabres.2011.06.020
49. Benedict C. R., Mathew B., Rex K. A., Cartwright J. Jr., Sordahl L. A., Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circulation Research 1986 58 1 58 67 2-s2.0-0022652492 (Pubitemid 16165933)
50. Golino P., Piscione F., Benedict C. R., Anderson H. V., Cappelli-Bigazzi M., Indolfi C., Condorelli M., Chiariello M., Willerson J. T., Local effect of serotonin released during coronary angioplasty. New England Journal of Medicine 1994 330 8 523 528 2-s2.0-0028085279 10.1056/NEJM199402243300802 (Pubitemid 24058954)